Form 4: Immunic Inc. Director Richard Alan Rudick Acquires 100,000 Stock Options
SEC Form 4 Filing
Director Richard Alan Rudick reports acquisition of 100,000 stock options in Immunic, Inc.
Summary
- Richard Alan Rudick, a director of Immunic, Inc., filed a Form 4 with the SEC.
- The filing reports the acquisition of 100,000 stock options on June 11, 2024, at an exercise price of $1.27.
- These options vest monthly over one year and expire on June 11, 2034.
- Rudick directly owns 100,000 shares of Immunic, Inc. common stock following the reported transaction.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard regulatory filing indicating a director's acquisition of stock options, which is neither overtly positive nor negative.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.
Stakeholder Impact
- The acquisition of stock options by a director may have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/11/2024 | Date of stock option grant and transaction. |
| 06/11/2034 | Expiration date of the stock options. |
| 06/12/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.